102 related articles for article (PubMed ID: 18347556)
1. Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling.
Mamounas EP; Budd GT; Miller KD
Clin Adv Hematol Oncol; 2008 Feb; 6(2 Suppl 3):1-8. PubMed ID: 18347556
[TBL] [Abstract][Full Text] [Related]
2. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice.
Gradishar WJ; Hansen NM; Susnik B
Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-7. PubMed ID: 19536946
[TBL] [Abstract][Full Text] [Related]
3. Incorporating the Oncotype DX breast cancer assay into community practice: An expert Q & A and case study sampling.
Mamounas E; Budd GT; Miller K
Clin Adv Hematol Oncol; 2008 Feb; 6(2):s1-s8. PubMed ID: 18516819
[No Abstract] [Full Text] [Related]
4. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
5. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
[TBL] [Abstract][Full Text] [Related]
6. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
Kaklamani V
Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
[TBL] [Abstract][Full Text] [Related]
7. Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm.
Rayhanabad JA; Difronzo LA; Haigh PI; Romero L
Am Surg; 2008 Oct; 74(10):887-90. PubMed ID: 18942607
[TBL] [Abstract][Full Text] [Related]
8. Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.
Markopoulos C
Expert Rev Anticancer Ther; 2013 Feb; 13(2):179-94. PubMed ID: 23406559
[TBL] [Abstract][Full Text] [Related]
9. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?
Lee JJ; Shen J
Am Surg; 2011 Oct; 77(10):1364-7. PubMed ID: 22127090
[TBL] [Abstract][Full Text] [Related]
10. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling in breast cancer.
Morris SR; Carey LA
Curr Opin Oncol; 2007 Nov; 19(6):547-51. PubMed ID: 17906450
[TBL] [Abstract][Full Text] [Related]
12. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS
Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
[TBL] [Abstract][Full Text] [Related]
13. The present and future of gene profiling in breast cancer.
Espinosa E; Gámez-Pozo A; Sánchez-Navarro I; Pinto A; Castañeda CA; Ciruelos E; Feliu J; Vara JA
Cancer Metastasis Rev; 2012 Jun; 31(1-2):41-6. PubMed ID: 22124734
[TBL] [Abstract][Full Text] [Related]
14. Prediction of benefit from adjuvant treatment in patients with breast cancer.
Eng-Wong J; Isaacs C
Clin Breast Cancer; 2010; 10 Suppl 1():E32-7. PubMed ID: 20587405
[TBL] [Abstract][Full Text] [Related]
15. Understanding tumor profiling and assessing treatment.
Hyams DM
Manag Care; 2008 Jul; 17(7 Suppl 7):4-8; discussion 17-8. PubMed ID: 19093336
[TBL] [Abstract][Full Text] [Related]
16. Commercialized multigene predictors of clinical outcome for breast cancer.
Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
18. Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks.
Roukos DH; Ziogas DE; Katsios C
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1187-95. PubMed ID: 20735306
[TBL] [Abstract][Full Text] [Related]
19. Can we approach zero relapse in breast cancer?
Mamounas EP
Oncologist; 2005 Oct; 10 Suppl 2():9-17. PubMed ID: 16272454
[TBL] [Abstract][Full Text] [Related]
20. [Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases].
Roy JA; Piccart MJ
Rev Med Brux; 1995; 16(4):242-4. PubMed ID: 7481234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
